Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that bicalutamide mesotherapy resulted in subtle hair density improvements and was well tolerated by premenopausal women with androgenetic alopecia.

This case report describes a 23-year-old Asian woman with fluoxetine non-responsive trichotillomania who showed significant improvement with bupropion and cognitive behavior therapy, though confirmation in larger trials is needed.

This study found that a combination of betulin and cytostatic Namitecan had a statistically significant synergistic effect on solid Ehrlich adenocarcinoma tumors in NMRI mice, and suggests a promising method for administering betulin in in vivo experiments despite its water insolubility.

This article discusses the potential of oral bicalutamide as a promising treatment for female pattern hair loss and reports no new clinical results.

This study suggests that oral budesonide may not effectively maintain remission in Crohn's disease beyond three months, with minor benefits that are outweighed by increased rates of treatment-related adverse events.

In this randomized, placebo-controlled study, Kūlaris supplementation significantly improved quality of life for participants with mild-to-severe acne over 12 weeks, though no significant changes in general skin health measures were observed compared to placebo.

This article discusses the discontinuation of the Bexxar regimen for non-Hodgkin's lymphoma, noting that despite its effectiveness, it was under-prescribed due to marketing and development challenges without reporting new clinical results.

This study found that among the tested analogs, compound 4e was the most effective in inhibiting wax esters in vivo in the Golden Syrian hamster ear model.

This review discusses the potential biomedical and clinical applications of brassinosteroids, highlighting their observed antiviral, anticancerous, and other bioactivities in animal test systems, but reports no new findings.

This study reported that the compound (1R, 2S)-4-(2-cyano-cyclohexyl-oxy)-2-trifluoromethyl-benzonitrile effectively stimulated hair growth in mice and reduced sebum production in hamsters.

This source explores the potential use of oral bicalutamide for treating female pattern hair loss, but specific results or outcomes from the study are not reported in the abstract.

This review highlights bicalutamide as a promising oral therapy for female pattern hair loss, noting its safety, tolerability, and effectiveness in women with hyperandrogenic symptoms like acne and hirsutism, though further trials are needed to confirm its ideal dose and efficacy.

In this study, the anti-wrinkle effect of bone morphogenetic protein receptor 1a extracellular domain was significantly greater than that of retinoic acid in a mouse model, suggesting potential for BMP antagonists in skin or hair treatments.

This study introduced a novel nonsteroidal androgen receptor antagonist that effectively controls sebum production in the golden Syrian hamster ear model through targeted follicular delivery.

This study reports that 4-(alkylthio)- and 4-(arylthio)-benzonitriles showed moderate sebum reduction as androgen receptor antagonists when applied topically in a validated animal model.

This review highlights that bicalutamide, a non-steroidal antiandrogen used in prostate cancer treatment, is mainly effective through its (R)-enantiomer and emphasizes the need to monitor its adverse effects despite its targeted antiandrogenic action.

Among cultured sebocytes, this study found that bilobetin significantly inhibited lipid production induced by IGF-1, suggesting potential for use in acne treatment.

This pharmacovigilance study found that certain systemic medications, including finasteride, bortezomib, and dupilumab, were disproportionately reported in association with eyelid disorders like blepharitis, meibomian gland dysfunction, and chalazia, suggesting these drugs may contribute to these conditions though benefits might still outweigh the risks.

In this study, bicalutamide at low doses was not linked to significant liver enzyme changes compared to other androgen-blocking treatments in transfeminine adolescents and young adults, suggesting its safety with careful monitoring for this population over one year.

RF-mesotherapy with bicalutamide may be a promising new treatment for hair loss.

In preclinical studies, a B-Raf inhibitor called WYE-130600 caused dose-related skin effects in dogs and rats, suggesting potential similar responses might occur in humans.

In this study on C3H/HeJ-engrafted mice, a single injection of BMD-1141 significantly increased anagen hair follicle counts and enhanced hair regrowth compared to daily high-dose ruxolitinib, suggesting it stimulates hair growth by influencing the hair cycle rather than altering immune response.

This study found that topical bortezomib increased cell proliferation in hair follicles and sebaceous glands in mice and may activate hair keratin gene expression through GATA-3 transcription factors.

This study found that trametinib and vemurafenib increased sebum production and gene expression related to lipid accumulation in hamster sebocytes, which may help explain certain side effects in patients.

This case series evaluated the use of oral bicalutamide with low-dose oral minoxidil in women with female pattern hair loss who didn't respond to minoxidil alone, finding that 96.6% showed improvement after six months without adverse effects.

This study reviewed evidence on eribulin's efficacy and safety for treating metastatic triple-negative breast cancer, highlighting variable survival outcomes and manageable safety profiles for both monotherapy and combination therapies.

Bicalutamide may improve hair growth in postmenopausal women with mild side effects.

This study reports the first successful use of zanubrutinib to treat a 15-year-old Chinese girl with severe refractory Evans' syndrome, resulting in a sustained recovery of platelet counts and haemoglobin levels.